Key facts
- CynosBio’s last known valuation is $26.9M.
- It has raised $12.8M; the latest was Later Stage VC ($11.1M) in Jul 2024.
- Notable investors include Mitsubishi UFJ Capital, Nippon Venture Capital, Sumitomo Mitsui Trust Bank, 77 Capital, Axil Capital Partners — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for CynosBio
- ·The full record, as it builds
Funding rounds
No funding rounds for CynosBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CynosBio
Developer of regenerative medicine technology designed for knee osteoarthritis. The company develops human autologous oral mucosa-derived epithelial cell sheets using human amniotic membrane substrate, with medicines for the treatment of traumatic cartilage damage, enabling the healthcare industry to help them from development support to clinical application.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2015
- Website
- cynosbio.com/
- Ownership
- Privately Held (backing)
CynosBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CynosBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CynosBio in its N-PORT filings yet. We sweep new filings monthly.